Home > Press > Bayer MaterialScience strengthens position in carbon nanotubes
Abstract:
Greater freedom for development of new areas of application:
Bayer MaterialScience strengthens position in carbon nanotubes
License agreement with U.S.-based company Hyperion concluded
Bayer MaterialScience is strengthening its position in developing new areas of application for carbon nanotubes (CNT). The company concluded a patent license agreement for the use of these materials with U.S. based company Hyperion Catalysis International, Inc. The agreement will help to solidify the leading positions of both companies in research and development as well as production technology for high-quality CNT-based products. Financial terms were not disclosed.
"We see high demand for materials with extraordinary material properties," said Dr. Joachim Wolff, Member of the Executive Committee at Bayer MaterialScience. "Developments using Baytubes® carbon nanotubes represent a key technology of the future for such requirements profile, and we are optimistic that we can offer our customers innovative and long-term solutions in these areas."
Baytubes® carbon nanotubes can be used as additives in established materials such as plastics and metal. They are versatile due to their unique property profile - from enhanced electrical and thermal conductivity to exceptional mechanical load bearing capacity. Among other things, Baytubes® CNT can help to increase endurance and efficiency of lithium-ion batteries, which in turn opens up their strong potential for use in energy-efficient electro-mobility concepts.
As one of the world's leading manufacturers of polymers and high-performance plastics, Bayer MaterialScience recognized the huge potential of nanotechnology early on. It has carried out intensive research into carbon nanotube production processes. Based in Cambridge, Massachusetts, U.S.A., Hyperion has been active in the field of carbon nanotubes since 1983 and currently holds a comprehensive portfolio of patents and patent applications covering a broad technology range, from CNT manufacturing to a variety of current and future applications.
David M. Wohlstadter, Hyperion's Vice President of Business Development stated, "We are quite pleased to have entered into this arrangement with Bayer MaterialScience. This license with BMS will further leverage Hyperion's broad patent portfolio and capitalize on the ever increasing demand for carbon nanotubes. We feel Bayer MaterialScience is well positioned to serve and help increase this demand, while Hyperion remains committed to expanding its own sales and providing its customers with the highest quality carbon nanotube based products."
####
About Bayer MaterialScience
With 2010 sales of EUR 10.2 billion, Bayer MaterialScience is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction and the sports and leisure industries. At the end of 2010, Bayer MaterialScience had 30 production sites and employed approximately 14,400 people around the globe. Bayer MaterialScience is a Bayer Group company.
About Hyperion Catalysis International, Inc.:
Headquartered in Cambridge, Massachusetts, U.S.A., Hyperion has been manufacturing and marketing its FIBRIL™ carbon nanotubes for a wide range of applications since 1983. The flagship FIBRIL™ technology is a conductive, multi-walled CNT based on the pioneering work in this field by Dr. Howard G. Tennent. Hyperion has devoted substantial resources to the development, improvement and patenting of the technology of their manufacture and the use of carbon nanotubes in a variety of applications.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For more information, please click here
Contacts:
Bayer MaterialScience AG
Stefan Paul Mechnig
Tel. +49 214 30-36352
Copyright © Bayer MaterialScience
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanotubes/Buckyballs/Fullerenes/Nanorods/Nanostrings
Tests find no free-standing nanotubes released from tire tread wear September 8th, 2023
Detection of bacteria and viruses with fluorescent nanotubes July 21st, 2023
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||